The Drug That Ended 30 Years of “Undruggable”: Rasonque Posts $197.6 Million in Its First Five Weeks
That word no longer applies. But the launch figures are only the most visible proof of something deeper: a molecular mechanism that may ultimately reshape treatment for the full spectrum of RAS-driven cancers — an addressable patient population vastly larger than…